John R Ohlfest

US Patent:

20130323300, Dec 5, 2013

Filed:

Oct 25, 2011

Appl. No.:

13/881712

Inventors:

Karen H. Ohlfest - Roseville MN, US
Walter Low - Saint Paul MN, US
John R. Ohlfest - Saint Paul MN, US

Assignee:

Regents of the University of Minnesota - Saint Paul MN

International Classification:

A61K 35/30
C07K 16/18
A61K 31/495
A61K 45/06
A61K 31/573
A61K 31/4375

US Classification:

424450, 4241741, 4242771, 4242781, 424 937, 435174, 435375, 514 90, 5303897

Abstract:

The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).

US Patent:

20130331546, Dec 12, 2013

Filed:

Oct 7, 2011

Appl. No.:

13/878023

Inventors:

John R. Ohlfest - Minneapolis MN, US
Michael R. Olin - New Brighton MN, US

International Classification:

A61K 38/17

US Classification:

530350

Abstract:

The present invention provides compositions and methods that involve the 36 kDa annexin II monomer, which has been identified as having immunostimulatory properties. Accordingly, in one aspect, the invention provides compositions that include at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that include administering to a subject a composition that includes at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that induce an in situ increase in the 36 kDa annexin II monomer by administering to a subject an amount of composition effective to induce localized hypoxia sufficient to cause a localized increase in annexin II.

US Patent:

20080124366, May 29, 2008

Filed:

Aug 6, 2007

Appl. No.:

11/834483

Inventors:

John R. Ohlfest - Coon Rapids MN, US
Walter C. Low - Shorewood MN, US
Wei Chen - Edina MN, US

International Classification:

A61K 39/00
A61K 31/7052
A61K 45/00
A61K 38/21
A61K 35/74
A61K 35/76
A61P 35/04

US Classification:

4242781, 514 44, 424 855, 424780, 424 936, 4242771

Abstract:

The present invention is based on the finding that toll-like receptor (TLR) agonists affect immune responses in a subject. The compositions and methods of the present invention include administering to the subject a therapeutically effective amount of a tumor lysate or tumor lysis agent in conjunction with a therapeutically effective amount of a TLR agonist.

US Patent:

20160263207, Sep 15, 2016

Filed:

Apr 21, 2016

Appl. No.:

15/135292

Inventors:

- Minneapolis MN, US
John R. Ohlfest - Minneapolis MN, US
Walter Low - Minneapolis MN, US

Assignee:

REGENTS OF THE UNIVERSITY OF MINNESOTA - Minneapolis MN

International Classification:

A61K 39/00
A61K 41/00
A61K 31/495
C12N 5/095
C07K 16/30
A61K 9/00
A61K 39/39
A61K 31/437
A61K 31/573

Abstract:

The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).

US Patent:

20160068533, Mar 10, 2016

Filed:

Sep 3, 2015

Appl. No.:

14/844833

Inventors:

- Minneapolis MN, US
John Ohlfest - Minneapolis MN, US
Courtney Aldrich - Minneapolis MN, US

Assignee:

REGENTS OF THE UNIVERSITY OF MINNESOTA - Minneapolis MN

International Classification:

C07D 487/04
A61K 39/39

Abstract:

The invention provides compounds of formula I:wherein R-R, R, and Rhave any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties.

US Patent:

20150283244, Oct 8, 2015

Filed:

Mar 12, 2013

Appl. No.:

14/387178

Inventors:

Karen H. Ohlfest - Roseville MN, US
- Minneapolis MN, US
John R. Ohlfest - Minneapolis MN, US

Assignee:

Regents of the University of Minnesota - Minneapolis MN

International Classification:

A61K 47/34
C08G 65/332
A61K 39/00
C08G 63/664
A61K 31/192
A61K 38/38

Abstract:

The invention provides semi-solid systems for delivering biologically active materials that include a polymer comprising 1) one or more units of formula Ia, IIa, or IIIa: (formula Ia, IIa, IIIa) and 2) one or more units comprising polycaprolactone; wherein R and Rhave any of the values defined in the application.

US Patent:

20150191525, Jul 9, 2015

Filed:

Nov 17, 2014

Appl. No.:

14/543714

Inventors:

Alan L. Epstein - Pasadena CA, US
Peisheng Hu - Covina CA, US
John Ohlfest - Roseville MN, US

International Classification:

C07K 14/705
A61K 38/22
A61K 39/395
C07K 14/575
A61K 39/00
A61K 38/17

Abstract:

Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof.